Saving Sight in Neovascular AMD: The Latest in Clinical Trials and Best Practices (CME Monograph)

Activity Description

By 2030, it is estimated that 3.7 million people in the United States will have advanced age-related macular degeneration, including neovascular age-related macular degeneration (nAMD) and geographic atrophy. Current treatments for nAMD leave much to be desired in terms of efficacy and treatment burden. New and emerging treatments for nAMD use novel molecules, delivery modalities, and targets to achieve better treatment longevity and reduced treatment burden. These include a DARPin (designed ankyrin repeat protein) (abicipar pegol), a small anti–vascular endothelial growth factor (VEGF) monoclonal antibody fragment (brolucizumab), an implantable delivery system (ranibizumab port delivery), and a monoclonal antibody with multiple angiogenic targets (faricimab). Vision maintenance, change in best-corrected visual acuity, and retinal fluid resolution are among the end points being explored vs traditional anti-VEGF agents in phase 2 and 3 clinical trials, with promising results. Developing retreatment plans for patients should balance fluid resolution and injection burden, considering a treat-and-extend approach. This activity captures the proceedings of a live roundtable discussion of expert retina specialists held during the Angiogenesis, Exudation, and Degeneration 2020 meeting. The desired results of this educational activity are for retina specialists and other ophthalmologists to evaluate emerging treatment strategies for nAMD in the context of the current standard of care.

Target Audience

This educational activity is intended for retina specialists and other ophthalmologists caring for patients with nAMD.

Learning Objectives

Upon completion of this activity, participants will be better able to:

  • Describe the mechanism of extended therapeutic effect for investigational treatments for nAMD
  • Discuss clinical trial data for approved and emerging treatments for nAMD
  • Develop retreatment plans for patients with nAMD guided by recent clinical trial results
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
07/01/2020
Course expires: 
07/31/2021

Program Chair and Moderator

Nancy M. Holekamp, MD
Professor of Clinical Ophthalmology
Washington University School of Medicine
Director, Retina Services
Pepose Vision Institute
St Louis, Missouri

Faculty

David Eichenbaum, MD
Collaborative Associate Professor of Ophthalmology
Morsani College of Medicine
University of South Florida
Partner and Director of Research
Retina Vitreous Associates of Florida
Tampa, Florida

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada, Reno School of Medicine
Reno, Nevada

Michael Singer, MD
Clinical Professor of Ophthalmology
University of Texas Health Science Center
Director of Clinical Research
Medical Center Ophthalmology Associates
San Antonio, Texas

Disclosure Policy Statement

It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of the educational activity in which they are participating. They are also required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. New York Eye and Ear Infirmary of Mount Sinai is committed to providing its learners with quality CME activities and related materials that promote improvements in healthcare and not the proprietary interests of a commercial interest and, thus, has established policies and procedures in place that identify and resolve all conflicts of interest prior to the execution or release of its educational activities. Full disclosure of faculty/planners and their commercial relationships, if any, follows.

Faculty

David Eichenbaum, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alimera Sciences; Allergan; Clearside Biomedical, Inc; D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.; EyePoint Pharmaceuticals; Genentech, Inc; Gyroscope; Kodiak Sciences Inc; Notal Vision; Novartis Pharmaceuticals Corporation; Recens Medical; and Regeneron Pharmaceuticals, Inc; Contracted Research: Alimera Sciences; Allergan; Chengdu Kanghong Pharmaceutical Group Co Ltd; Clearside Biomedical, Inc; Genentech, Inc; Gyroscope; IVERIC bio; Kodiak Sciences Inc; Mylan NV; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; and Opthea; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Allergan; D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.; Genentech, Inc; and Novartis Pharmaceuticals Corporation; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): Clearside Biomedical, Inc; and Hemera Biosciences.

Nancy M. Holekamp, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Receipt of Intellectual Rights/Patent Holder: Katalyst Healthcares & Life Sciences; Consultant/Advisory Board: Acucela Inc; Allergan; Clearside Biomedical, Inc; Gemini Therapeutics; Genentech, Inc; Gyroscope; Katalyst Healthcares & Life Sciences; Lineage Cell Therapeutics; Notal Vision; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals, Inc; Contracted Research: Gemini Therapeutics; Genentech, Inc; Gyroscope; and Notal Vision; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Allergan; Genentech, Inc; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc; and Spark Therapeutics, Inc; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): Katalyst Healthcares & Life Sciences.

Arshad M. Khanani, MD, MA, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon; Adverum; Allegro Ophthalmics, LLC; Allergan; Bausch & Lomb Incorporated; EyePoint Pharmaceuticals; Gemini Therapeutics; Genentech, Inc; GrayBug, Inc; Gyroscope; Kodiak Sciences Inc; Novartis Pharmaceuticals Corporation; Opthea; Oxurion NV; PolyPhotonix; Recens Medical; and Regenxbio Inc; Contracted Research: Adverum; Allegro Ophthalmics, LLC; Allergan; Gemini Therapeutics; Genentech, Inc; GrayBug, Inc; Gyroscope; IVERIC bio; Kodiak Sciences Inc; Novartis Pharmaceuticals Corporation; Opthea; Oxurion NV; Recens Medical; and Regenxbio Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Allergan; and Novartis Pharmaceuticals Corporation.

Michael Singer, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Allergan; Ampio Pharmaceuticals Inc; Apellis Pharmaceuticals; Clearside Biomedical, Inc; Genentech, Inc; Ionis Pharmaceuticals, Inc; Kodiak Sciences Inc; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc; Santen Inc; and Spark Therapeutics, Inc; Contracted Research: Aerie Pharmaceuticals, Inc; Allergan; Ampio Pharmaceuticals Inc; Apellis Pharmaceuticals; Clearside Biomedical, Inc; Genentech, Inc; Ionis Pharmaceuticals, Inc; Kodiak Sciences Inc; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc; Santen Inc; and Spark Therapeutics, Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; Allergan; Ampio Pharmaceuticals Inc; Apellis Pharmaceuticals; Clearside Biomedical, Inc; Genentech, Inc; Ionis Pharmaceuticals, Inc; Kodiak Sciences Inc; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc; Santen Inc; and Spark Therapeutics, Inc.

New York Eye and Ear Infirmary of Mount Sinai Peer Review Disclosure

Gennady Landa, MD, has no relevant commercial relationships to disclose.

Editorial Support Disclosures

Erika Langsfeld, PhD; Cynthia Tornallyay, RD, MBA, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.

Medical Writer: Tony Realini, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; iSTaR; New World Medical, Inc; and Notal Vision.

Disclosure Attestation

The contributing physicians listed above have attested to the following:

  1. that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
  2. that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
  3. that all reasonable clinical alternatives will be discussed when making practice recommendations.

Accreditation Statement

imageThe New York Eye and Ear Infirmary of Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This educational activity was developed and implemented in collaboration with MedEdicus LLC.

AMA Credit Designation Statement

The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Grantor Statement

This continuing medical education activity is supported through an unrestricted educational grant from Allergan.

Off-Label Discussion

This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies

https://www.nyee.edu/education/cme

CME Provider Contact Information

For questions about this activity, call 917-270-7571.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, Allergan, or Retina.

This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 213

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Please login or register to take this course.

Clicking Register indicates that you have reviewed the CME information for this activity.

Learning Method and Medium

This educational activity consists of a supplement and ten (10) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 1.5 hours to complete.